COMPARISON OF FORMIC ACID PUNCTURE TO INTRALESIONAL MMR VACCINE FOR TREATING COMMON WARTS

Abstract

approaches. There are many different treatment options available, but no single approach has been shown to be totally
successful.
Aim: The purpose of this study was to compare the safety and effectiveness of treating common warts with an
intralesional injection of the MMR vaccination vs an 85% formic acid puncture.
Methods: The 120 participants in the study were split into two groups of 60, with Group I receiving the intralesional
dose of the MMR vaccine (0.3% ml per lesion) and Group II receiving an 85% formic acid puncture in each lesion,
with a maximum of 10 warts managed in each case. To check for recurrence, five visits were conducted every two
weeks, followed by a three-month follow-up.
Results: The study's findings demonstrated that, in Group I, complete, partial, and no responses were observed in
62.5% (n=), 8% (n=), and 4.1% (n=) of the subjects, respectively. In Group II, on the other hand, complete, partial,
and no responses were observed in 31.8% (n=), 63.6% (n=), and 4.5% (n=) of the subjects, respectively. With p=0.02,
the treatment response rate difference between the two groups was statistically significant. During follow-up, no
recurrence was observed in any group.
Conclusions: This study shows that intralesional MMR vaccination immunotherapy is a straightforward, safe,
economical, and successful way to treat warts. It also shows statistically significant improvements in cure rates when
compared to formic acid treatment.